Evidence map›Paper›PMID 29531642›Full record

ArticleInternational journal of organ transplantation medicine2018

One-year Allograft and Patient Survival in Renal Transplant Recipients Receiving Antiplatelet Therapy at the Time of Transplantation.

T Benkö, M Gottmann, S Radunz, A Bienholz, F H Saner, J W Treckmann, A Paul, D P Hoyer

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of organ transplantation medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Management of antithrombotic therapies in kidney transplantation candidates and recipients: an ERBP clinical practice document by the DESCaRTES Working Group of ERA and the EKITA Committee of ESOT.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Guideline
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

T BenköDepartment of General, Visceral and Transplantation Surgery, University Hospital Essen, University Essen-Duisburg, Germany.
M GottmannDepartment of General, Visceral and Transplantation Surgery, University Hospital Essen, University Essen-Duisburg, Germany.
S RadunzDepartment of General, Visceral and Transplantation Surgery, University Hospital Essen, University Essen-Duisburg, Germany.
A BienholzDepartment of Nephrology, University Hospital Essen, University Essen-Duisburg, Germany.
F H SanerDepartment of General, Visceral and Transplantation Surgery, University Hospital Essen, University Essen-Duisburg, Germany.
J W TreckmannDepartment of General, Visceral and Transplantation Surgery, University Hospital Essen, University Essen-Duisburg, Germany.
A PaulDepartment of General, Visceral and Transplantation Surgery, University Hospital Essen, University Essen-Duisburg, Germany.
D P HoyerDepartment of General, Visceral and Transplantation Surgery, University Hospital Essen, University Essen-Duisburg, Germany.
Essen University Hospital · DEUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntiplatelet therapy is common in patients on the waiting list for kidney transplantation.

objectiveTo evaluate the incidence of post-operative bleeding in patients with antiplatelet therapy undergoing kidney transplantation and analyze the impact on the outcome.

methodsWe studied all patients with concomitant antiplatelet therapy undergoing kidney transplantation in our center from January 2007 to June 2012. Data were collected by chart review. Univariate and multivariate logistic regression and Cox proportional hazard model were used to identify risk factors for the long-term outcome.

resultsOf 744 kidney transplant recipients during the study period, 161 received oral antiplatelet therapy and were included in the study. One-third of the patients demonstrated signs of bleeding, half of which requiring surgical treatment. Coronary artery disease, deceased donor kidney transplantation, and dual antiplatelet medication were independent risk factors for post-operative bleeding. One-year allograft survival was significantly better in the non-bleeding group (91.4%

conclusionThis analysis indicated a high risk for post-operative bleeding in renal transplant patients under antiplatelet therapy. The associated negative effect on allograft survival underscored the need to reduce any risk factors for post-operative bleeding.

Indexed as

Graft survivalKidney transplantationPlatelet aggregation inhibitorsPostoperative complicationsPostoperative period

Identifiers

PMID29531642
PMCPMC5839625
OpenAlexW2977259659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.